Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from AIM ImmunoTech ( (AIM) ) is now available.
On February 5, 2026, AIM ImmunoTech furnished investors with a February 2026 corporate presentation, a year-end interim clinical progress update on its DURIPANC program, and a related press release, providing a consolidated view of its current development activities rather than formal, liability-bearing filings. The company highlighted ongoing work on a Phase I/II open-label study combining durvalumab (Imfinzi) and its drug candidate rintatolimod (Ampligen) in pancreatic cancer patients with stable disease following FOLFIRINOX, while emphasizing that Ampligen remains under investigation, that significant additional testing and human trials are required, and that numerous regulatory, clinical, operational and international risks could materially affect future outcomes for the program and its stakeholders.
The most recent analyst rating on (AIM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Underperform.
The score is primarily weighed down by very weak financial performance (large losses, negative equity, and ongoing cash burn). Technicals also remain unfavorable with a broader downtrend and negative MACD, while valuation is constrained by negative earnings and no dividend support. A recent corporate update further underscored significant development and funding/regulatory risks.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
AIM ImmunoTech Inc. is a biopharmaceutical company focused on developing its investigative drug Ampligen for the potential treatment of multiple types of viral diseases, cancers and immune-deficiency disorders, with a pipeline of clinical trials aimed at establishing its efficacy across these indications.
Average Trading Volume: 108,264
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.46M
For an in-depth examination of AIM stock, go to TipRanks’ Overview page.